Board of Directors of DOR BioPharma, Inc. Engages RBC Capital Markets to Evaluate and Negotiate Cell Therapeutics, Inc.’ Unsolicited Proposal to Acquire DOR BioPharma, Inc.

MIAMI, FL -- (MARKET WIRE) -- March 06, 2007 -- DOR BioPharma, Inc. ("DOR" or the "Company") (OTCBB: DORB) announced that it has engaged RBC Capital Markets Corporation ("RBC") to assist in the evaluation and potential negotiation of the unsolicited acquisition proposal from Cell Therapeutics. DOR has retained RBC to provide advice in response to new and improved acquisition interest from Cell Therapeutics, Inc. and other unnamed parties.